Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]4FN PET/CT Imaging in Graft Versus Host Disease
NCT07325253Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2025
- Primary completion
- Jan 2028
- Modality
- CA (Contrast Agent), PET (Positron Emission Tomography)
- Countries
- 1
01
Overview
Phase 2, open-label trial of 4-[18F]fluoro-1-naphthol in graft-versus-host disease (GVHD) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events at 1 year. Started Nov 2025; status: recruiting.
02
Drugs
4-[18F]fluoro-1-naphthol
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07325253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07325253.